# Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

> **NCT00126555** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Skin Cancer
- Squamous Cell Carcinoma of the Skin

## Interventions

- **DRUG:** Gefitinib
- **RADIATION:** Radiotherapy
- **PROCEDURE:** Conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00126555
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126555, "Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00126555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*